Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiragolumab and Atezolizumab in SMARCB1 or SMARCA4 Deficient Tumors
NCT05286801Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Nov 2022
- Primary completion
- Mar 2030
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 3
01
Overview
Phase 2, open-label trial of tiragolumab in SMARCB1-deficient tumor and SMARCA4-deficient undifferentiated carcinoma (SMARCA4-UT) (2 arms), sponsored by National Cancer Institute. Primary endpoints: Dose Limiting Toxicities of Tiragolumab Monotherapy at 21 days, Objective Response Rate at 5 years and 1 more. Started Nov 2022; status: active, not recruiting.
02
Drugs
tiragolumab
03
Conditions
SMARCB1-deficient tumorSMARCA4-deficient undifferentiated carcinoma (SMARCA4-UT)
Beyond the preview
Go deeper on NCT05286801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05286801.